Possible liver injury added to label of Biogen MS drug

Jan 25 (Reuters) - The prescribing label for Biogen Inc's

big-selling oral multiple sclerosis drug Tecfidera has

been updated to include a warning of potential liver injury

that could require hospitalization, the company said on

Wednesday.

Read more